Israini Wiyulanda Iskandar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Israini Wiyulanda Iskandar has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Nasrum Massi
Department of Clinical Microbiology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
4 shared publications Irda Handayani
Department of Clinical Pathology, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia
2 shared publicationsJamaluddin Fitrah Alam
Faculty of Marine Science and Fisheries, Universitas Hasanuddin, Makassar, Indonesia
2 shared publications- Najdah Hidayah
Biomedical Science Study Program, Graduate School of Hasanuddin University, Makassar, Indonesia
2 shared publications Sulfahri
2 shared publications- Sulfahri
Faculty of Mathematics and Natural Sciences, Hasanuddin University, Makassar, Indonesia
2 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Narra Sains Indonesia in Narra J
- Vol. 5  (1) , e1130
Computational drug repurposing for tuberculosis by inhibiting Ag85 complex proteins
Tuberculosis (TB) remains a significant and deadly infection among pulmonary diseases caused by Mycobacterium tuberculosis, a highly adaptive bacterium. The ability of M. tuberculosis to evade certain drugs has been linked to its unique structure, particularly in the cell envelope, where the Ag85 complex proteins play an essential role in this part. The aim of this study was to utilize a drug repurposing strategy targeting the Ag85 complex proteins. This study utilized a computational approach with 120 selected drugs experimentally identified to inhibit Tuberculosis. A virtual screening molecular docking with Autodock Vina was used to filter the compounds and identify the strong binders to the Ag85 Complex. Molecular dynamics simulations employed the Gromacs Packages to evaluate the stability of each complex, including root mean square deviation (RMSD), root mean square fluctuation (RMSF), and radius of gyration (RoG). Additionally, absorption, distribution, metabolism, excretion, and toxicity (ADMET) assessments were conducted to gather more information about the drug-likeness of each hit compound. Three compounds, selamectin, imatinib, and eltrombopag were selected as potential drugs repurposed to inhibit the activity of the Ag85 complex enzyme, with binding affinities ranging between -10.560 kcal/mol and -11.422 kcal/mol. The MD simulation within 100 ns (3 replicas) showed that the average RMSD of each Ag85A complex was 0.15 nm–0.16 nm, RMSF was 0.09 nm–0.10 nm, and RoG was 1.80 nm–1.81 nm. For Ag85B, the average RMSD was 1.79 nm–1.80 nm, RMSF was 0.08 nm–0.09 nm, and RoG was 1.79 nm – 1.80 nm. Then, for Ag85C, the mean RMSD was 0.16 nm–0.18 nm, RMSF was 0.09, and RoG was 1.77 nm. The study highlights that these promising results demonstrate the potential of some repurposed drugs in combating the Ag85 complex.
- 1 January 2025
- Published by Narra Sains Indonesia in Narra J
- Vol. 5  (1) , e1130
Open AccessComputational drug repurposing for tuberculosis by inhibiting Ag85 complex proteins
Tuberculosis (TB) remains a significant and deadly infection among pulmonary diseases caused by Mycobacterium tuberculosis, a highly adaptive bacterium. The ability of M. tuberculosis to evade certain drugs has been linked to its unique structure, particularly in the cell envelope, where the Ag85 complex proteins play an essential role in this part. The aim of this study was to utilize a drug repurposing strategy targeting the Ag85 complex proteins. This study utilized a computational approach with 120 selected drugs experimentally identified to inhibit Tuberculosis. A virtual screening molecular docking with Autodock Vina was used to filter the compounds and identify the strong binders to the Ag85 Complex. Molecular dynamics simulations employed the Gromacs Packages to evaluate the stability of each complex, including root mean square deviation (RMSD), root mean square fluctuation (RMSF), and radius of gyration (RoG). Additionally, absorption, distribution, metabolism, excretion, and toxicity (ADMET) assessments were conducted to gather more information about the drug-likeness of each hit compound. Three compounds, selamectin, imatinib, and eltrombopag were selected as potential drugs repurposed to inhibit the activity of the Ag85 complex enzyme, with binding affinities ranging between -10.560 kcal/mol and -11.422 kcal/mol. The MD simulation within 100 ns (3 replicas) showed that the average RMSD of each Ag85A complex was 0.15 nm–0.16 nm, RMSF was 0.09 nm–0.10 nm, and RoG was 1.80 nm–1.81 nm. For Ag85B, the average RMSD was 1.79 nm–1.80 nm, RMSF was 0.08 nm–0.09 nm, and RoG was 1.79 nm – 1.80 nm. Then, for Ag85C, the mean RMSD was 0.16 nm–0.18 nm, RMSF was 0.09, and RoG was 1.77 nm. The study highlights that these promising results demonstrate the potential of some repurposed drugs in combating the Ag85 complex.
- Open Access
- 27 August 2024
- Published by Narra Sains Indonesia in Narra J
- Vol. 4  (3) , e889
Association between vitamin D levels with IL-6 and IL-10 in umbilical cord blood of infants
A worldwide issue, vitamin D deficiency affects pregnant mothers and babies everywhere, including Indonesia. It involves the adaptive immune system by controlling the production of pro- and anti-inflammatory cytokines and the balance between humoral (Th2) and cell-mediated (Th1) immunity. The aim of this study was to investigate the relationship between vitamin D and the cytokines IL-6 and IL-10 in infants. It also examined the relationship between ferritin and IL-6/IL-10 in newborns. The study collected 114 umbilical cord blood samples from term-born mothers without clinical symptoms. IL-6 and IL-10 were among the cytokine profiles measured by the enzyme-linked immunosorbent assay (ELISA). SPSS was used for statistical analysis, and an in-silico investigation was carried out to examine the molecular relationships between vitamin D and IL-6/IL-10. Using the 20 ng/mL as the cut-off for vitamin D insufficiency suggested the insignificant association of vitamin D with IL-6 (p=0.42), IL-10 (p=0.76), and ferritin (p=0.47). When the umbilical cord vitamin D level was categorized into four quartiles, the association with the highest statistical significance (quartile 4 versus quartile 2) was observed for IL-6 (p<0.001), IL-10 (p<0.001), and ferritin (p<0.001). However, the linear regression did not suggest the significant correlations of vitamin D with IL-6 (p=0.40) and IL-10 (p=0.45). A significant correlation based on the linear regression was found between ferritin and IL-10 (p=0.03). Molecular docking studies demonstrated binding affinities of -8.04 kcal/mol for IL-6-vitamin D and -8.53 kcal/mol for IL-10-vitamin D complexes, with stable root mean square deviation throughout the simulations. This study contributes valuable insights into the clinical and computational analysis of the relationship of vitamin D with IL-6 or IL-10.
- 27 August 2024
- Published by Narra Sains Indonesia in Narra J
- Vol. 4  (3) , e889
Open AccessAssociation between vitamin D levels with IL-6 and IL-10 in umbilical cord blood of infants
A worldwide issue, vitamin D deficiency affects pregnant mothers and babies everywhere, including Indonesia. It involves the adaptive immune system by controlling the production of pro- and anti-inflammatory cytokines and the balance between humoral (Th2) and cell-mediated (Th1) immunity. The aim of this study was to investigate the relationship between vitamin D and the cytokines IL-6 and IL-10 in infants. It also examined the relationship between ferritin and IL-6/IL-10 in newborns. The study collected 114 umbilical cord blood samples from term-born mothers without clinical symptoms. IL-6 and IL-10 were among the cytokine profiles measured by the enzyme-linked immunosorbent assay (ELISA). SPSS was used for statistical analysis, and an in-silico investigation was carried out to examine the molecular relationships between vitamin D and IL-6/IL-10. Using the 20 ng/mL as the cut-off for vitamin D insufficiency suggested the insignificant association of vitamin D with IL-6 (p=0.42), IL-10 (p=0.76), and ferritin (p=0.47). When the umbilical cord vitamin D level was categorized into four quartiles, the association with the highest statistical significance (quartile 4 versus quartile 2) was observed for IL-6 (p<0.001), IL-10 (p<0.001), and ferritin (p<0.001). However, the linear regression did not suggest the significant correlations of vitamin D with IL-6 (p=0.40) and IL-10 (p=0.45). A significant correlation based on the linear regression was found between ferritin and IL-10 (p=0.03). Molecular docking studies demonstrated binding affinities of -8.04 kcal/mol for IL-6-vitamin D and -8.53 kcal/mol for IL-10-vitamin D complexes, with stable root mean square deviation throughout the simulations. This study contributes valuable insights into the clinical and computational analysis of the relationship of vitamin D with IL-6 or IL-10.
- Open Access
- 1 December 2023
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 8  (4) , 527-533
microRNA hsa-miR-425-5p and hsa-miR-4523 expressions as biomarkers of active pulmonary tuberculosis, latent tuberculosis infection, and lymph node tuberculosis
Studies on miRNA highlight its significance as an immunomarker for several diseases, including tuberculosis. This study aimed to determine the difference between miR-425-5p and miR-4523 expressions in patients with active pulmonary TB (PTB), latent TB infection (LTBI), and lymph node TB (LNTB), whose diagnosis remains challenging. This case–control study was performed on blood samples obtained from 23 patients with PTB, 21 with LTBI, 21 with LNTB, and 25 healthy controls (HC). miRNA hsa-miR-425-5p and hsa-miR-4523 expression levels were measured by RT-qPCR. Statistical analyses were performed using SPSS version 25.0. RT-qPCR showed that hsa-mir-425-5p and hsa-mir-4523 expression levels were significantly different among the four groups (PTB, LTBI, LNTB, and HCs). The hsa-mir-425-5p miRNA expression level in LNTB was higher than that in LTBI (p = 0.003). Meanwhile, the hsa-mir-4523 miRNA expression was downregulated in PTB and LNTB than in LTBI (p < 0.0001 and p = 0.015, respectively). The ROC analysis of a single sample showed that only mir-4523 could discriminate LTBI and HCs, with an AUC of 0.829 (p < 0.001). The ROC curve of each miRNA was further analyzed after logistic regression by adjusting for sex and age. The combination of both miRNAs was also analyzed. The model that analyzed the combination of both miRNAs after adjusting for age had the best performance in differentiating LNTB from LTBI, with an AUC of 0.97 (p < 0.001). miRNA hsa-mir-425-5p was upregulated and miRNA hsa-mir-4523 was downregulated in PTB and LNTB than in LTBI.
- 1 December 2023
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 8  (4) , 527-533
Open AccessmicroRNA hsa-miR-425-5p and hsa-miR-4523 expressions as biomarkers of active pulmonary tuberculosis, latent tuberculosis infection, and lymph node tuberculosis
Studies on miRNA highlight its significance as an immunomarker for several diseases, including tuberculosis. This study aimed to determine the difference between miR-425-5p and miR-4523 expressions in patients with active pulmonary TB (PTB), latent TB infection (LTBI), and lymph node TB (LNTB), whose diagnosis remains challenging. This case–control study was performed on blood samples obtained from 23 patients with PTB, 21 with LTBI, 21 with LNTB, and 25 healthy controls (HC). miRNA hsa-miR-425-5p and hsa-miR-4523 expression levels were measured by RT-qPCR. Statistical analyses were performed using SPSS version 25.0. RT-qPCR showed that hsa-mir-425-5p and hsa-mir-4523 expression levels were significantly different among the four groups (PTB, LTBI, LNTB, and HCs). The hsa-mir-425-5p miRNA expression level in LNTB was higher than that in LTBI (p = 0.003). Meanwhile, the hsa-mir-4523 miRNA expression was downregulated in PTB and LNTB than in LTBI (p < 0.0001 and p = 0.015, respectively). The ROC analysis of a single sample showed that only mir-4523 could discriminate LTBI and HCs, with an AUC of 0.829 (p < 0.001). The ROC curve of each miRNA was further analyzed after logistic regression by adjusting for sex and age. The combination of both miRNAs was also analyzed. The model that analyzed the combination of both miRNAs after adjusting for age had the best performance in differentiating LNTB from LTBI, with an AUC of 0.97 (p < 0.001). miRNA hsa-mir-425-5p was upregulated and miRNA hsa-mir-4523 was downregulated in PTB and LNTB than in LTBI.
- Open Access
- 31 August 2023
- Published by Narra Sains Indonesia in Narra J
- Vol. 3  (2) , e179
Green algae Caulerpa racemosa compounds as antiviral candidates for SARS-CoV-2: In silico study
Green algae (Caulerpa racemosa) are known to contain bioactive compounds which are hypothesized to have antiviral activities against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) pandemic. The aim of this study was to analyze the anti-SARS-CoV-2 potential of compounds extracted from the green alga Caulerpa racemosa using in silico analysis. The extract was obtained through maceration with 96% ethanol and the compounds present in the extract were identified through gas chromatography-mass spectroscopy (GC-MS). The binding affinities were analyzed in silico using the PyRx application and visualized in the PyMOL software. GC-MS analysis of Caulerpa racemosa extract showed 92 spectral peaks, each of which was assigned to a bioactive compound. Of the six compounds with a strong binding affinity, n-[1-(1-adamantan-1-yl-propyl)-2,5-dioxo-4-trifluoromethyl-imidazo lidin-4-yl] 4-methoxy-benzamide had the lowest score (-8.1 kcal/mol) against the SARS-CoV-2 3C-like protease binding site, similar with that of remdesivir. The molecular dynamics calculations demonstrated that root means square deviation values of the selected inhibitors remained stable throughout a 15-nanosecond simulation. In conclusion, the in silico analysis suggests that Caulerpa racemosa extract is a potential antiviral candidate against SARS-CoV-2.
- 31 August 2023
- Published by Narra Sains Indonesia in Narra J
- Vol. 3  (2) , e179
Open AccessGreen algae Caulerpa racemosa compounds as antiviral candidates for SARS-CoV-2: In silico study
Green algae (Caulerpa racemosa) are known to contain bioactive compounds which are hypothesized to have antiviral activities against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) pandemic. The aim of this study was to analyze the anti-SARS-CoV-2 potential of compounds extracted from the green alga Caulerpa racemosa using in silico analysis. The extract was obtained through maceration with 96% ethanol and the compounds present in the extract were identified through gas chromatography-mass spectroscopy (GC-MS). The binding affinities were analyzed in silico using the PyRx application and visualized in the PyMOL software. GC-MS analysis of Caulerpa racemosa extract showed 92 spectral peaks, each of which was assigned to a bioactive compound. Of the six compounds with a strong binding affinity, n-[1-(1-adamantan-1-yl-propyl)-2,5-dioxo-4-trifluoromethyl-imidazo lidin-4-yl] 4-methoxy-benzamide had the lowest score (-8.1 kcal/mol) against the SARS-CoV-2 3C-like protease binding site, similar with that of remdesivir. The molecular dynamics calculations demonstrated that root means square deviation values of the selected inhibitors remained stable throughout a 15-nanosecond simulation. In conclusion, the in silico analysis suggests that Caulerpa racemosa extract is a potential antiviral candidate against SARS-CoV-2.
- Open Access
Docking Studies and Molecular Dynamics Simulations of Potential Inhibitors from the Brown Seaweed Sargassum polycystum (Phaeophyceae) against PLpro of SARS-CoV-2
The COVID-19 disease is a major problem affecting human health all over the world. Consequently, researchers have been trying to find solutions to treat this pandemic-scale disease. Even if there are vaccines and approved drugs that could decrease the spread of this pandemic, multidisciplinary approaches are still needed to identify new small molecules as alternatives to combat COVID-19, especially those from nature. In this study, we employed computational approaches by screening 17 natural compounds from the tropical brown seaweed Sargassum polycystum known to have anti-viral properties that benefit human health. This study assessed some seaweed natural products that are bound to the PLpro of SARS-CoV-2. By employing pharmacophore and molecular docking, these natural compounds from S. polycystum showed remarkable scores for protein targets with competitive scores compared to X-ray crystallography ligands and well-known antiviral compounds. This study provides insightful information for advanced study and further in vitro examination and clinical investigation for drug development prospects of abundant yet underexploited tropical seaweeds.
Open AccessDocking Studies and Molecular Dynamics Simulations of Potential Inhibitors from the Brown Seaweed Sargassum polycystum (Phaeophyceae) against PLpro of SARS-CoV-2
The COVID-19 disease is a major problem affecting human health all over the world. Consequently, researchers have been trying to find solutions to treat this pandemic-scale disease. Even if there are vaccines and approved drugs that could decrease the spread of this pandemic, multidisciplinary approaches are still needed to identify new small molecules as alternatives to combat COVID-19, especially those from nature. In this study, we employed computational approaches by screening 17 natural compounds from the tropical brown seaweed Sargassum polycystum known to have anti-viral properties that benefit human health. This study assessed some seaweed natural products that are bound to the PLpro of SARS-CoV-2. By employing pharmacophore and molecular docking, these natural compounds from S. polycystum showed remarkable scores for protein targets with competitive scores compared to X-ray crystallography ligands and well-known antiviral compounds. This study provides insightful information for advanced study and further in vitro examination and clinical investigation for drug development prospects of abundant yet underexploited tropical seaweeds.
- Open Access
- 1 December 2022
- Published by IOP Publishing in IOP Conference Series: Earth and Environmental Science
- Vol. 1119  (1)
Molecular docking analysis of selected natural products from Halymenia sp. and Laurencia sp. seaweeds against plasmepsins as antimalarials
Malaria is one of the most important public health problems worldwide, with nearly half of the global population exposed to the risk of contamination. The disease is found in 91 countries, mostly in the tropics and subtropics of the planet. There are several previous research that identifies Plasmepsins as a potential target to develop novel antimalarial drugs from the malaria parasite Plasmodium that play a role in the breakdown of globin into amino acids. Given the above, it is important to find novel and effective drugs that can decrease this disease, especially from natural products such as medicine. Seaweed is a potential source of bioactive compounds to be used as antimalarials, such as species from the genera Laurencia and Halymenia. This recent study has studied the molecular docking approach to identify the potential of Halymenia sp. and Laurencia sp. against Plasmepsin by using PyRx 0.8 software. It showed that the compounds in Halymenia sp. and Laurencia sp. were able to react and inhibit the action of plasmepsin, seen from the binding affinity value, which was quite small at -4.3, this value is higher than the two bioactive compounds in seaweed, namely Stigmasterol and p-hydroxybenzaldehyde which have binding affinity values of -8.5 and 6.5, respectively. Judging from this, the compounds contained in Laurencia sp and Halymenia sp have potential as candidates for antimalarial drugs.
- 1 December 2022
- Published by IOP Publishing in IOP Conference Series: Earth and Environmental Science
- Vol. 1119  (1)
Open AccessMolecular docking analysis of selected natural products from Halymenia sp. and Laurencia sp. seaweeds against plasmepsins as antimalarials
Malaria is one of the most important public health problems worldwide, with nearly half of the global population exposed to the risk of contamination. The disease is found in 91 countries, mostly in the tropics and subtropics of the planet. There are several previous research that identifies Plasmepsins as a potential target to develop novel antimalarial drugs from the malaria parasite Plasmodium that play a role in the breakdown of globin into amino acids. Given the above, it is important to find novel and effective drugs that can decrease this disease, especially from natural products such as medicine. Seaweed is a potential source of bioactive compounds to be used as antimalarials, such as species from the genera Laurencia and Halymenia. This recent study has studied the molecular docking approach to identify the potential of Halymenia sp. and Laurencia sp. against Plasmepsin by using PyRx 0.8 software. It showed that the compounds in Halymenia sp. and Laurencia sp. were able to react and inhibit the action of plasmepsin, seen from the binding affinity value, which was quite small at -4.3, this value is higher than the two bioactive compounds in seaweed, namely Stigmasterol and p-hydroxybenzaldehyde which have binding affinity values of -8.5 and 6.5, respectively. Judging from this, the compounds contained in Laurencia sp and Halymenia sp have potential as candidates for antimalarial drugs.
- Open Access
- 23 August 2021
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 14  (11) , 103393
Potential bioactive compounds as SARS-CoV-2 inhibitors from extracts of the marine red alga Halymenia durvillei (Rhodophyta) – A computational study
The respiratory infection COVID-19 caused by the virus SARS CoV-2 has continued to be a major health problem worldwide and has caused more than a million mortalities. Even if the development of COVID-19 vaccines has shown much progress, efforts to find novel, natural anti-viral drugs should be pursued. Halymenia durvillei is a marine red alga widely distributed around Southeast Asia. This study aimed to develop new anti SARS CoV-2 compounds from ethanolic and ethyl acetate extracts of H. durvillei via a computational approach, focusing onthe inhibitory action against the main protease (3CL-Mpro). In this study, 37 compounds were extracted and identified by GC–MS analysis. The potentials of compounds 1–2 tetradecandiol and E,E,Z-1,3,12-nonadecatriene-5,14-diol were identified for therapeutic purposes based on our pharmacophore study, while cholest-5-En-3-Ol (3.Beta.)- had a high fitness score in molecular docking studies both in monomer and dimer state compared to the N3 inhibitor and remdesivir affinity scores. As these compounds show competitive affinity scores against the 3CL-Mpro, these natural compounds may be effective for the treatment of COVID-19 infection. The ADME and pharmacokinetic studies should also be employed to assess the ability of the natural compounds as oral drugs. These promising results have shown the potentials of H. durvillei as an alternative drug in addressing COVID-19 infection. Accordingly, further studies should explore the effectiveness of these active compounds.
- 23 August 2021
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 14  (11) , 103393
Open AccessPotential bioactive compounds as SARS-CoV-2 inhibitors from extracts of the marine red alga Halymenia durvillei (Rhodophyta) – A computational study
The respiratory infection COVID-19 caused by the virus SARS CoV-2 has continued to be a major health problem worldwide and has caused more than a million mortalities. Even if the development of COVID-19 vaccines has shown much progress, efforts to find novel, natural anti-viral drugs should be pursued. Halymenia durvillei is a marine red alga widely distributed around Southeast Asia. This study aimed to develop new anti SARS CoV-2 compounds from ethanolic and ethyl acetate extracts of H. durvillei via a computational approach, focusing onthe inhibitory action against the main protease (3CL-Mpro). In this study, 37 compounds were extracted and identified by GC–MS analysis. The potentials of compounds 1–2 tetradecandiol and E,E,Z-1,3,12-nonadecatriene-5,14-diol were identified for therapeutic purposes based on our pharmacophore study, while cholest-5-En-3-Ol (3.Beta.)- had a high fitness score in molecular docking studies both in monomer and dimer state compared to the N3 inhibitor and remdesivir affinity scores. As these compounds show competitive affinity scores against the 3CL-Mpro, these natural compounds may be effective for the treatment of COVID-19 infection. The ADME and pharmacokinetic studies should also be employed to assess the ability of the natural compounds as oral drugs. These promising results have shown the potentials of H. durvillei as an alternative drug in addressing COVID-19 infection. Accordingly, further studies should explore the effectiveness of these active compounds.
- Open Access
- 1 October 2019
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 1341  (2) , 022012
Biosugar Production From Algae Spirogyra peipingensis by acid and enzymatic hydrolysis processes
Spirogyra peipingensis, green algae, is a suitable feedstock for biosugar production. This study analyzes biosugar production by the hydrolysis of S. peipingensis conducted by acid and enzymatic hydrolysis processes. Acid hydrolysis process was conducted by H2SO4 0,2 M acid with various concentrations (0,2,4,6,8, dan 10%). Enzymatic hydrolysis process was held by using amylase enzyme with vary concentrations (0,25,50,75,100 dan 125 KNU). The result showed that the hydrolysis process with H2SO4 acid generates higher sugar concentration than compared with the amylase enzyme. Enzymatic hydrolysis method produces the optimum sugar concentration which is made up 0,45 g/g in adding α-amylase enzyme 50 KNU. In contrast, hydrolysis acid process able to produce the optimum sugar concentration in 0,55 g/g in adding of H2SO4 10% 0,2 M acid.
- 1 October 2019
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 1341  (2) , 022012
Open AccessBiosugar Production From Algae Spirogyra peipingensis by acid and enzymatic hydrolysis processes
Spirogyra peipingensis, green algae, is a suitable feedstock for biosugar production. This study analyzes biosugar production by the hydrolysis of S. peipingensis conducted by acid and enzymatic hydrolysis processes. Acid hydrolysis process was conducted by H2SO4 0,2 M acid with various concentrations (0,2,4,6,8, dan 10%). Enzymatic hydrolysis process was held by using amylase enzyme with vary concentrations (0,25,50,75,100 dan 125 KNU). The result showed that the hydrolysis process with H2SO4 acid generates higher sugar concentration than compared with the amylase enzyme. Enzymatic hydrolysis method produces the optimum sugar concentration which is made up 0,45 g/g in adding α-amylase enzyme 50 KNU. In contrast, hydrolysis acid process able to produce the optimum sugar concentration in 0,55 g/g in adding of H2SO4 10% 0,2 M acid.